Botulinum toxin type A in the treatment of neuropathic pain in a case of postherpetic neuralgia;Toxina botulínica tipo A en el tratamiento del dolor neuropático en un caso de neuralgia postherpética

Neurologia

Volumn 23, Issue 4, 2008, Pages 259-262

  Ruiz Huete, C ^a   Bermejo, Pedro Emilio ^a  

^a Clinica Nuestra Senora del Rosario   (Spain)

Author keywords

Neuropathic pain; Neurotoxin botulinum; Postherpetic neuralgia

Indexed keywords

BOTULINUM TOXIN A;

ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; CASE REPORT; DRUG INDICATION; DRUG TOLERABILITY; DYSTONIA; FEMALE; HUMAN; MIGRAINE; NEUROPATHIC PAIN; POSTHERPETIC NEURALGIA; SPASTICITY; TIC; TREATMENT OUTCOME;

AGED, 80 AND OVER; BOTULINUM TOXIN TYPE A; FEMALE; HUMANS; NEURALGIA, POSTHERPETIC; NEUROMUSCULAR AGENTS;

EID: 46049098847     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Hansson P. Neuropathic pain: clinical characteristics and diagnostic workup. Eur J Pain 2002;6:47-50.
2. Carneado-Ruiz J, Morera-Guitart J, Alfaro-Sáez A, Turpin-Fenoll L, Serna-Candel C, Matías-Guiu Guía J. El dolor neuropático como motivo de consulta en neurología: análisis de su frecuencia. Rev Neurol 2005;41:643-8.
3. Bermejo Velasco PE, Velasco Calvo R. Nuevos fármacos antiepilépticos y dolor neuropático. De la medicina molecular a la clínica. Med Clin (Barc) 2007;129:542-50.
4. Lim ECh, Seet RC. Botulinum toxin, Quo Vadis? Med Hypotheses 2007;69:718-23.
5. Jost WH. Other indications of botulinum toxin therapy. Eur J Neurol 2006;13:65-9.
6. Argoff CE. A focused review on the use of botulinum toxins for neuropathic pain. Clin J Pain 2002;18:177-81.
7. Liu HT, Tsai SK, Kao MC, Hu JS. Botulinum toxin A relieved neuropathic pain in a case of post-herpetic neuralgia. Pain Med 2006;7:89-91.
8. Jabbari B, Maher N, Difazio MP. Botulinum toxin A improved burning pain and allodynia in two patients with spinal cord pathology. Pain Med 2003;4:206-10.
9. Tsai CP, Liu CY, Lin KP, Wang KC. Efficacy of botulinum toxin type A in the relief of carpal tunnel syndrome: a preliminary experience. Clin Drug Investig 2006;26:511-5.
10. Piovesan EJ, Teive HG, Kowacs PA, Della Coletta MV, Werneck LC, Silberstein SD. An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology 2005;65:1306-8.
11. Volcy M, Tepper SJ, Rapoport AM, Sheftell FD, Bigal ME. Botulinum toxin A for the treatment of greater occipital neuralgia and trigeminal neuralgia: a case report with pathophysiological considerations. Cephalalgia 2006;26:336-40.
12. Luvisetto S, Marinelli S, Cobianchi S, Pavone F. Anti-allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain. Neuroscience 2007;145:1-4.
13. Park HJ, Lee Y, Lee J, Park C, Moon DE. The effects of botulinum toxin A on mechanical and cold allodynia in a rat model of neuropathic pain. Can J Anaesth 2006;53:470-7.
14. Meunier FA, Lisk G, Sesardic D, Dolly JO. Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation. Mol Cell Neurosci 2003;22:454-66.
15. Lee SE, Kim JH. Involvement of substance P and calcitonin gene-related peptide in development and maintenance of neuropathic pain from spinal nerve injury model of rat. Neurosci Res 2007;58:245-9.
16. Hou YP, Zhang YP, Song YF, Zhu CM, Wang YC, Xie GL. Botulinum toxin type A inhibits rat pyloric myoelectrical activity and substance P release in vivo. Can J Physiol Pharmacol 2007;85:209-14.
17. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000;38:245-58.
18. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005;26:785-93.
19. Meng J, Wang J, Lawrence G, Dolly JO. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci 2007;120:2864-74.
20. Bird GC, Han JS, Fu Y, Adwanikar H, Willis WD, Neugebauer V. Pain-related synaptic plasticity in spinal dorsal horn neurons: role of CGRP. Mol Pain 2006;2:31.
21. Mense S. Neurobiological basis for the use of botulinum toxin in pain therapy. J Neurol 2004;251:1-7.
22. Bozzi Y, Costantin L, Antonucci F, Caleo M. Action of botulinum neurotoxins in the central nervous system: antiepileptic effects. Neurotox Res 2006;9:197-203.
23. Gibbs JL, Diogenes A, Hargreaves KM. Neuropeptide Y modulates effects of bradykinin and prostaglandin E2 on trigeminal nociceptors via activation of the Y1 and Y2 receptors. Br J Pharmacol 2007;150:72-9.